Ray McDermott
Impact in
- Oncology top 0.2%
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- PARP inhibition in cancer therapy
- Pulmonary and Respiratory Medicine top 0.1%
- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Gastric Cancer Management and Outcomes
Papers in
-
- Prostate Cancer Treatment and Research 52
- Renal cell carcinoma treatment 19
- Sarcoma Diagnosis and Treatment 15
- Lung Cancer Treatments and Mutations 13
- Oncology 71
- Cancer Immunotherapy and Biomarkers 14
- Pancreatic and Hepatic Oncology Research 12
- Colorectal Cancer Treatments and Studies 11
- Co-authors
- Thierry André (8 shared papers)Scott Kopetz (7 shared papers)Michael James Overman (7 shared papers)Sara Lonardi (7 shared papers)Rebecca Anne Moss (5 shared papers)Zhu Alexander Cao (5 shared papers)Heinz‐Josef Lenz (5 shared papers)Jean-Marie Ledeine (4 shared papers)
- Journals
- Annals of Oncology (42 papers)The Lancet Oncology (11 papers)European Urology (9 papers)Journal of Clinical Oncology (9 papers)Cancers (9 papers)
- Partner nations
- IrelandUnited StatesFrance
In The Last Decade
Ray McDermott
202 papers receiving 20.4k citations
Ray McDermott's Hit Papers
Peers
Comparison fields: 5 of 119
- Oncology 7.8k
- Pulmonary and Respiratory Medicine 7.5k
- Cancer Research 1k
- Surgery 2.2k
- Pathology and Forensic Medicine 885
Countries citing papers authored by Ray McDermott
This map shows the geographic impact of Ray McDermott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ray McDermott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ray McDermott more than expected).
Fields of papers citing papers by Ray McDermott
This network shows the impact of papers produced by Ray McDermott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ray McDermott. The network helps show where Ray McDermott may publish in the future.
Co-authors
The 25 scholars most cited alongside Ray McDermott, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 211 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2019 | 2674 |
| 2 | Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study Hit paper breakdown → | 2017 | 2301 |
| 3 | Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer Hit paper breakdown → | 2018 | 1691 |
| 4 | Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer Hit paper breakdown → | 2019 | 1188 |
| 5 | Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial Hit paper breakdown → | 2018 | 1060 |
| 6 | Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trials Hit paper breakdown → | 2020 | 814 |
| 7 | Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2023 | 728 |
| 8 | Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma Hit paper breakdown → | 2021 | 698 |
| 9 | Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial Hit paper breakdown → | 2020 | 592 |
| 10 | Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration Hit paper breakdown → | 2020 | 561 |
| 11 | Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design Hit paper breakdown → | 2022 | 560 |
| 12 | Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial Hit paper breakdown → | 2021 | 490 |
| 13 | 2017 | 464 | |
| 14 | Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial Hit paper breakdown → | 2023 | 446 |
| 15 | Docetaxel-Resistance in Prostate Cancer: Evaluating Associated Phenotypic Changes and Potential for Resistance Transfer via Exosomes Hit paper breakdown → | 2012 | 400 |
| 16 | Lenvatinib plus pembrolizumab versus lenvatinib plus placebo for advanced hepatocellular carcinoma (LEAP-002): a randomised, double-blind, phase 3 trial Hit paper breakdown → | 2023 | 326 |
| 17 | Rucaparib or Physician’s Choice in Metastatic Prostate Cancer Hit paper breakdown → | 2023 | 319 |
| 18 | 2020 | 309 | |
| 19 | Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma Hit paper breakdown → | 2017 | 305 |
| 20 | Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial Hit paper breakdown → | 2022 | 212 |
About Ray McDermott
Ray McDermott is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Pathology and Forensic Medicine and Surgery, having authored 211 papers that have together received 20.8k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (52 papers), Renal cell carcinoma treatment (19 papers), Sarcoma Diagnosis and Treatment (15 papers), Cancer Genomics and Diagnostics (15 papers), Cancer Immunotherapy and Biomarkers (14 papers), Lung Cancer Treatments and Mutations (13 papers), Pancreatic and Hepatic Oncology Research (12 papers) and Colorectal Cancer Treatments and Studies (11 papers). The work is most often cited by research in Oncology (7.8k citations), Pulmonary and Respiratory Medicine (7.5k citations), Cancer Research (1k citations), Surgery (2.2k citations) and Pathology and Forensic Medicine (885 citations). Ray McDermott has collaborated with scholars based in Ireland, United States and France. Frequent co-authors include Thierry André, Scott Kopetz, Michael James Overman, Sara Lonardi, Rebecca Anne Moss, Zhu Alexander Cao, Heinz‐Josef Lenz, Jean-Marie Ledeine, Michael Andrew Morse and Jayesh Desai. Their work appears in journals such as Annals of Oncology, The Lancet Oncology, European Urology, Journal of Clinical Oncology and Cancers.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.